We are international
Donate
TEXT SIZE   


ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)
Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain
12.07.11


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles